Dianthus Therapeutics (DNTH) News Today $20.00 +0.79 (+4.11%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Significant Growth in Short InterestDianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 6,000,000 shares, an increase of 6.0% from the December 15th total of 5,660,000 shares. Based on an average trading volume of 250,800 shares, the days-to-cover ratio is currently 23.9 days. Approximately 31.2% of the company's stock are short sold.January 19 at 10:18 PM | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.5% - Time to Sell?Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 5.5% - Here's What HappenedJanuary 14, 2025 | marketbeat.comBarclays PLC Acquires 33,185 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Barclays PLC raised its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 390.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,684 shares of the company's stock after acquiring an additional 33,185January 14, 2025 | marketbeat.comDianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | globenewswire.comDianthus Therapeutics (NASDAQ:DNTH) Trading Down 6.8% - Should You Sell?Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 6.8% - Here's WhyJanuary 7, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Shares Up 7.8% - Should You Buy?Dianthus Therapeutics (NASDAQ:DNTH) Trading 7.8% Higher - Here's WhyJanuary 6, 2025 | marketbeat.comJane Street Group LLC Takes $556,000 Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Jane Street Group LLC purchased a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 20,316 shares of the company's stock, valued at approximately $556,000. Jane Street Group LLC owneJanuary 6, 2025 | marketbeat.comBarclays PLC Boosts Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Barclays PLC raised its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 390.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 41,684 shares of the company's stock after purchasing an additional 33,185 shares during the quarter. BarclaysDecember 30, 2024 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of "Buy" by BrokeragesDianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) has been given a consensus rating of "Buy" by the ten brokerages that are presently covering the stock, MarketBeat reports. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. TDecember 27, 2024 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 2.5% - What's Next?Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 2.5% - Should You Sell?December 26, 2024 | marketbeat.comState Street Corp Increases Stock Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)State Street Corp grew its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 101.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 821,131 shares of the company's stock after purchasing aDecember 23, 2024 | marketbeat.comTD Cowen Initiates Coverage of Dianthus Therapeutics (DNTH) with Buy RecommendationDecember 21, 2024 | msn.comForecasting The Future: 5 Analyst Projections For Dianthus TherapeuticsDecember 20, 2024 | benzinga.comDianthus Therapeutics (NASDAQ:DNTH) Coverage Initiated by Analysts at TD CowenTD Cowen began coverage on shares of Dianthus Therapeutics in a research note on Friday. They set a "buy" rating for the company.December 20, 2024 | marketbeat.comWellington Management Group LLP Invests $1.47 Million in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Wellington Management Group LLP purchased a new stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 53,785 shares of the compDecember 19, 2024 | marketbeat.comDianthus Therapeutics (DNTH) Receives a Buy from Stifel NicolausDecember 17, 2024 | markets.businessinsider.comDianthus Therapeutics (NASDAQ:DNTH) Upgraded to "Moderate Buy" at Raymond JamesRaymond James raised shares of Dianthus Therapeutics to a "moderate buy" rating in a report on Thursday.December 14, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Increases Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Charles Schwab Investment Management Inc. lifted its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 142.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16December 14, 2024 | marketbeat.comPoint72 Asset Management L.P. Buys 263,500 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Point72 Asset Management L.P. raised its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 151.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 437,700 shares of the company's stock after acquiring an additionalDecember 8, 2024 | marketbeat.comJanus Henderson Group PLC Grows Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Janus Henderson Group PLC grew its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 40.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 949,334 shares of the company's stock after purchasing anDecember 7, 2024 | marketbeat.comWalleye Capital LLC Acquires Shares of 30,000 Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Walleye Capital LLC bought a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 30,000 shares of the company's stock, valued at approximaDecember 7, 2024 | marketbeat.comHighVista Strategies LLC Makes New $542,000 Investment in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)HighVista Strategies LLC bought a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund bought 19,808 shares of the company's stock, valued at approximately $542,000. HighViDecember 4, 2024 | marketbeat.comPoint72 Asia Singapore Pte. Ltd. Sells 30,936 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Point72 Asia Singapore Pte. Ltd. lowered its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 78.3% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 8,568 shares of the company's stock after selling 30,936 shares during theDecember 4, 2024 | marketbeat.comBraidwell LP Buys 126,836 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Braidwell LP lifted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 34.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 493,687 shares of the company's stock after acquiring an aNovember 29, 2024 | marketbeat.comVestal Point Capital LP Sells 205,000 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Vestal Point Capital LP lowered its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 34.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 395,000 shares of the company's stock after selling 205,000 shares during the period. VNovember 29, 2024 | marketbeat.comGreat Point Partners LLC Has $7.53 Million Stock Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Great Point Partners LLC trimmed its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 63.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 275,000 shares of the company's stock aftNovember 27, 2024 | marketbeat.comDianthus TherapeuticsNovember 23, 2024 | forbes.comDianthus Therapeutics (NASDAQ:DNTH) Trading Up 5.1% - Should You Buy?Dianthus Therapeutics (NASDAQ:DNTH) Trading 5.1% Higher - What's Next?November 22, 2024 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest UpdateDianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) saw a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 5,100,000 shares, a growth of 7.8% from the October 15th total of 4,730,000 shares. Approximately 25.2% of the shares of the company are sold short. Based on an average trading volume of 191,600 shares, the days-to-cover ratio is presently 26.6 days.November 19, 2024 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 8.1% - Here's WhyDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 8.1% - Time to Sell?November 15, 2024 | marketbeat.comDianthus Therapeutics’ Strategic Advancements and Accelerated Drug Development Drive ‘Buy’ RatingNovember 14, 2024 | markets.businessinsider.comDianthus Therapeutics: Strategic Positioning and Financial Strength Underpin ‘Buy’ Rating Amidst Key Clinical DevelopmentsNovember 14, 2024 | markets.businessinsider.comWhat is HC Wainwright's Estimate for DNTH FY2024 Earnings?Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Analysts at HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for Dianthus Therapeutics in a research report issued on Monday, November 11th. HC Wainwright analyst S. Ramakanth now anticipates that the company will poNovember 14, 2024 | marketbeat.comDianthus price target raised to $52 from $48 at OppenheimerNovember 11, 2024 | markets.businessinsider.comDianthus Therapeutics (NASDAQ:DNTH) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a report on Monday.November 11, 2024 | marketbeat.comOppenheimer Boosts Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $52.00Oppenheimer upped their price target on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an "outperform" rating in a research note on Monday.November 11, 2024 | marketbeat.comBuy Recommendation for Dianthus Therapeutics: Strong Financial Position and Promising Drug PipelineNovember 8, 2024 | markets.businessinsider.comDianthus Therapeutics Reports Q3 Progress and FinancialsNovember 8, 2024 | markets.businessinsider.comA Glimpse Into The Expert Outlook On Dianthus Therapeutics Through 4 AnalystsNovember 8, 2024 | benzinga.comDianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $56.00Raymond James boosted their target price on Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an "outperform" rating in a report on Friday.November 8, 2024 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up - Still a Buy?Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up - Here's WhyNovember 8, 2024 | marketbeat.comDianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial ResultsNovember 7, 2024 | globenewswire.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of "Buy" by AnalystsShares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have earned a consensus recommendation of "Buy" from the ten ratings firms that are currently covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation and two have issued a strongNovember 7, 2024 | marketbeat.comDianthus Therapeutics to Participate in Three Upcoming Healthcare Investor ConferencesNovember 4, 2024 | finance.yahoo.comDianthus Therapeutics to Participate in Three Upcoming Healthcare Investor ConferencesNovember 4, 2024 | globenewswire.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 5% - Should You Buy?Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 5% - Should You Buy?October 15, 2024 | marketbeat.comDianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual MeetingOctober 15, 2024 | globenewswire.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.4% - Here's What HappenedDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.4% - Time to Sell?October 14, 2024 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Buy" from AnalystsShares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have received a consensus rating of "Buy" from the eleven analysts that are presently covering the company, Marketbeat.com reports. Nine equities research analysts have rated the stock with a buy recommendation and two have givenOctober 13, 2024 | marketbeat.comDianthus: Modest Opportunity With 2 CaveatsOctober 9, 2024 | seekingalpha.com Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address DNTH Media Mentions By Week DNTH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DNTH News Sentiment▼0.820.45▲Average Medical News Sentiment DNTH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DNTH Articles This Week▼33▲DNTH Articles Average Week Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Zai Lab News Bausch Health Companies News Recursion Pharmaceuticals News Catalyst Pharmaceuticals News Gemini Therapeutics News Twist Bioscience News HUTCHMED News Edgewise Therapeutics News Amneal Pharmaceuticals News Kymera Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DNTH) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
